Ligand validation:2HG9

CDL: CARDIOLIPIN

CDL is a Ligand Of Interest in 2HG9 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2HG9_CDL_M_800	1%	41%	0.509	0.628	1.18	1.13	4	6	1	0	81%	0.405
2GNU_CDL_M_1309	38%	22%	0.122	0.984	1.77	1.5	3	3	0	0	10%	10
7MH4_CDL_M_410	32%	79%	0.186	0.914	0.37	0.5	-	1	0	0	69%	0.69
1M3X_CDL_M_900	30%	59%	0.193	0.892	0.67	0.91	2	4	0	0	81%	0.81
1KBY_CDL_M_5000	29%	56%	0.21	0.901	0.73	0.94	1	5	1	0	81%	0.81
5LRI_CDL_M_710	28%	41%	0.198	0.892	1.17	1.12	4	4	0	0	78%	0.78
5Y5S_CDL_M_415	41%	34%	0.128	0.953	1.32	1.27	3	3	1	0	39%	0.39
3ZDQ_CDL_A_1721	37%	64%	0.215	0.943	0.72	0.65	4	4	0	1	84%	0.42
6JY3_CDL_B_301	33%	24%	0.163	0.908	1.53	1.57	5	14	0	0	64%	0.64
7COH_CDL_A_521	33%	72%	0.212	0.901	0.46	0.6	-	2	6	0	94%	0.94
7A0W_CDL_A_501	32%	37%	0.15	0.908	1.28	1.2	4	6	2	0	52%	0.52

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.